IGF2BP3 and renal cell carcinoma: Another study on renal cell carcinoma (RCC) revealed a different pathway, where IGF2BP3 stabilizes AGAP2-AS1, allowing it to competitively bind with miR-9-5p, consequently upregulating the expression of Thrombospondin-2 (THBS2) and activating the PI3K/AKT signaling pathway.